Cytarabine
Cytarabine, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase. Cytarabine inhibits DNA synthesis with an IC50 of 16 nM. Cytarabine has antiviral effects against HSV. Cytarabine shows anti-orthopoxvirus activity.
Product Specifications
CAS Number
[147-94-4]
Product Name Alternative
Cytosine β-D-arabinofuranoside; Cytosine Arabinoside; Ara-C
UNSPSC
12352005
Hazard Statement
H317, H361
Target
Apoptosis; Autophagy; DNA/RNA Synthesis; Endogenous Metabolite; HSV; Nucleoside Antimetabolite/Analog; Orthopoxvirus
Type
Natural Products
Related Pathways
Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/Cytarabine.html
Concentration
10mM
Purity
99.99
Smiles
O=C1N=C(C=CN1[C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)N
Molecular Formula
C9H13N3O5
Molecular Weight
243.22
Precautions
H317, H361
References & Citations
[1]Tobias, S.C. and R.F. Borch, Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol Pharm, 2004. 1 (2) : p. 112-6.|[2]Besirli, C.G., et al. Cytosine arabinoside rapidly activates Bax-dependent apoptosis and a delayed Bax-independent death pathway in sympathetic neurons. Cell Death Differ, 2003. 10 (9) : p. 1045-58.|[3]Yamauchi, H., et al., Involvement of p53 in 1-beta-D-arabinofuranosylcytosine-induced trophoblastic cell apoptosis and impaired proliferation in rat placenta. Biol Reprod, 2004. 70 (6) : p. 1762-7.|[4]Richel, D.J., et al., Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia. Br J Cancer, 1988. 58 (6) : p. 730-3.|[5]Shepshelovich D, et al. Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study. Br J Clin Pharmacol. 2015 Apr;79 (4) :685-91.|[6]Renis HE. Antiviral activity of cytarabine in herpesvirus-infected rats. Antimicrob Agents Chemother. 1973 Oct;4 (4) :439-44.|[7]Gruffaz M, Zhou S, Vasan K, et al. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications. mBio. 2018;9 (3) :e00756-18. Published 2018 May 8.|[8]Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57 (1-2) :41-52.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Natural Products
Clinical Information
Launched
Isoform
HSV-1; Microbial Metabolite
Citation 01
ACS Appl Mater Interfaces. 2023 Jan 11;15 (1) :452-468.|ACS Infect Dis. 2025 Oct 30.|Acta Biomater. 2023 Oct 15:170:288-302.|Acta Biomater. 2025 May 1:197:357-373.|Acta Pharmacol Sin. 2021 Jan;42 (1) :108-114.|Acta Pharmacol Sin. 2025 Jun;46 (6) :1733-1741.|Antioxid Redox Signal. 2025 Jun;42 (16-18) :933-953.|Arab J Chem. 2023 Jul 4, 105117.|Asian Pac J Cancer Prev. 2023 Jan 1;24 (1) :185-194.|Biochem Pharmacol. 2022 Apr:198:114948.|Biol Pharm Bull. 2021 Dec 1;44 (12) :1843-1850.|Biomed Mater. 2020 Apr 28;15 (3) :035016. |bioRxiv. 2023 Dec 15:2023.12.15.571909.|bioRxiv. 2024 June 28.|bioRxiv. 2024 September 19.|Blood Adv. 2024 Jan 9;8 (1) :112-129.|Blood Cancer Discov. 2025 Sep 3;6 (5) :464-483.|Br J Pharmacol. 2025 Jul 23.|Cancer Biol Ther. 2025 Dec;26 (1) :2459426.|Cancer Cell Int. 2024 Dec 26;24 (1) :430.|Cancer Cell. 2023 Dec 11;41 (12) :2136-2153.e13.|Cancer Lett. 2023 Jan 1:552:215981.|Cancers (Basel) . 2022 Oct 19;14 (20) :5127.|Cell Death Differ. 2022 Sep;29 (9) :1816-1833.|Cell Death Dis. 2021 Jan 5;12 (1) :20.|Cell Death Dis. 2022 Apr 20;13 (4) :379.|Cell Death Dis. 2025 Aug 13;16 (1) :616.|Cell Discov. 2023 Mar 7;9 (1) :26.|Cell Rep Med. 2024 May 29:101592.|Cell Rep Med. 2024 Sep 27:101770.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep Med. 2025 Sep 19:102365.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Cell Rep. 2025 Nov 25;44 (11) :116496.|Cell. 2018 Sep 20;175 (1) :171-185.e25.|Clin Chem. 2019 Dec;65 (12) :1522-1531. |Curr Med Sci. 2025 Jun;45 (3) :458-468.|Eur J Pharmacol. 2022 Feb 15:917:174722.|Eur J Pharmacol. 2023 Dec 15:961:176162.|Fish Shellfish Immunol. 2019 Sep;92:889-896.|Front Genet. 2021 Aug 5:12:678368.|Front Oncol. 2024 Jul 19:14:1440650.|Heliyon. 2024 Aug 13;10 (16) :e36140.|Immunity. 2025 Feb 11;58 (2) :465-480.e8.|Insect Biochem Mol Biol. 2025 Oct 17:185:104424.|Int J Biol Macromol. 2025 Dec;333 (Pt 2) :148750.|iScience. 2024 Jun 8;27 (7) :110221.|J Adv Res. 2025 May 10:S2090-1232 (25) 00309-1.|J Biol Chem. 2023 Jan;299 (1) :102798.|J Exp Clin Cancer Res. 2022 Dec 9;41 (1) :340.|J Leukoc Biol. 2025 May 16:qiaf065.|J Med Virol. 2025 Oct;97 (10) :e70655.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|J Nanobiotechnology. 2024 Aug 14;22 (1) :486.|J Virol. 2021 Mar 10;95 (7) :e01272-20.|Leukemia. 2021 Oct;35 (10) :2827-2839.|Leukemia. 2023 Jun;37 (6) :1336-1348.|Mol Brain. 2020 Dec 10;13 (1) :166.|Mol Carcinog. 2023 Oct;62 (10) :1546-1562.|Mol Carcinog. 2025 May;64 (5) :801-815.|Mol Neurobiol. 2025 Aug;62 (8) :10296-10309.|Mol Pharm. 2021 May 3;18 (5) :2015-2031.|Nat Cell Biol. 2024 Aug;26 (8) :1346-1358.|Nat Commun. 2024 Jul 7;15 (1) :5689.|Neurotox Res. 2021 Dec;39 (6) :2007-2017.|Ocul Surf. 2024 Oct:34:444-458.|Patent. US20240344035A1|Patent. US20240344035A1.|Res Sq. 2024 Jul 12.|Research Square Preprint. 2022 Jun.|Research Square Preprint. 2023 Oct 28.|Research Square Preprint. 2024 Aug 19.|Research Square Print. September 9th, 2022.|Sci Adv. 2025 Apr 18;11 (16) :eadu3956.|Sci Data. 2024 Sep 19;11 (1) :1024.|SLAS Discov. 2018 Aug;23 (7) :687-696. |Stem Cell Reports. 2021 Nov 9;16 (11) :2659-2673.|Stem Cells Dev. 2025 Apr;34 (7-8) :164-176.|Toxicol Appl Pharmacol. 2025 May:498:117305.|Transl Neurodegener. 2024 Aug 2;13 (1) :39.|Universidad De Salamanca. 2023|J Adv Res. 2025 May 21:S2090-1232 (25) 00358-3.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
